间变性淋巴瘤激酶
肺癌
背景(考古学)
克里唑蒂尼
医学
临床试验
后天抵抗
肿瘤科
疾病
癌症研究
生物信息学
癌症
生物
内科学
古生物学
恶性胸腔积液
作者
Malinda Itchins,Puey Ling Chia,SA Hayes,V. Howell,Anthony J. Gill,W. Cooper,Thomas John,Paul Mitchell,Michael Millward,Stephen Clarke,Benjamin Solomon,Nick Pavlakis
摘要
Since the identification of anaplastic lymphoma kinase (ALK) gene rearrangements in non-small cell lung cancer (NSCLC) in 2005, the treatment of ALK-rearranged NSCLC (ALK+ NSCLC) has evolved at a rapid pace. This molecularly distinct subset of NSCLC has uniquely important biology, clinicopathologic features and mechanisms of drug resistance which impact on the choice of treatment for a patient with this disease. There are multiple ALK tyrosine kinase inhibitors now available in clinical practice with efficacy data continuing to emerge and guide the optimal treatment algorithm. A detailed search of medical databases and clinical trial registries was conducted to capture all relevant articles on this topic enabling an updated detailed overview of the landscape of management of ALK-rearranged NSCLC.
科研通智能强力驱动
Strongly Powered by AbleSci AI